Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | KDM6B | O15054 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | IGF2R | P11717 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29527259 | 1.00 | PTPN1 (0.43) | PTPN1CA2PTPN2KDM6BGAA | |
| SCHEMBL207380 | 1.00 | PTPN1 (0.43) | PTPN1CA2PTPN2KDM6BGAA | |
| SCHEMBL27816756 | 1.00 | PTPN1 (0.43) | PTPN1CA2PTPN2KDM6BGAA | |
| SCHEMBL29528060 | 1.00 | PTPN1 (0.43) | PTPN1CA2PTPN2KDM6BGAA | |
| SCHEMBL2290293 | 1.00 | PTPN1 (0.43) | PTPN1CA2PTPN2KDM6BGAA | |
| SCHEMBL4267711 | 1.00 | PTPN1 (0.43) | PTPN1CA2PTPN2KDM6BGAA | |
| SCHEMBL4267718 | 1.00 | PTPN1 (0.43) | PTPN1CA2PTPN2KDM6BGAA | |
| SCHEMBL29527606 | 0.90 | SLC6A2 (0.44) | PTPN1CA2PTPN2KDM6BGAA | |
| SCHEMBL29527678 | 0.90 | PTPN1 (0.39) | PTPN1CA2PTPN2KDM6BGAA | |
| SCHEMBL29527771 | 0.88 | CD209 (0.38) | PTPN1CA2PTPN2KDM6BGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 561 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759456-B2 | Pharmaceutical composition | KOWA COMPANY, LTD. (JP) | 2023-09-19 | — | — | US | claimed |
| US-20200179346-A1 | PHARMACEUTICAL COMPOSITION | KOWA COMPANY, LTD. (JP) | 2020-06-11 | — | — | US | claimed |
| US-20200155514-A1 | PHARMACEUTICAL COMPOSITION | KOWA COMPANY, LTD. (JP) | 2020-05-21 | — | — | US | claimed |
| US-20200147209-A1 | ALUM-CONTAINING COATING FORMULATIONS FOR MICRONEEDLE VACCINE PATCHES | KINDEVA DRUG DELIVERY L.P. | 2020-05-14 | — | — | US | claimed |
| EP-3646867-A1 | PHARMACEUTICAL COMPOSITION | Kowa Company, Ltd. (JP) | 2020-05-06 | — | — | EP | claimed |
| US-10228341-B2 | Biosensor | ARKRAY, INC. (JP) | 2019-03-12 | — | — | US | claimed |
| US-20180008703-A1 | ALUM-CONTAINING COATING FORMULATIONS FOR MICRONEEDLE VACCINE PATCHES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-01-11 | — | — | US | claimed |
| EP-3250228-A1 | ALUM-CONTAINING COATING FORMULATIONS FOR MICRONEEDLE VACCINE PATCHES | 3M Innovative Properties Company (US) | 2017-12-06 | — | — | EP | claimed |
| CN-107206066-A | Aluminated coating agent for micropin vaccine patch | 3M创新有限公司 | 2017-09-26 | — | — | CN | claimed |
| WO-2016122915-A1 | ALUM-CONTAINING COATING FORMULATIONS FOR MICRONEEDLE VACCINE PATCHES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-08-04 | — | — | WO | claimed |
| US-20050256045-A1 | Apparatus and method for transdermal delivery of parathyroid hormone agents | ZOSANO PHARMA CORPORATION | 2005-11-17 | — | — | US | claimed |
| WO-2005102334-A2 | APPARATUS AND METHOD FOR TRANSDERMAL DELIVERY OF FENTANY-BASED AGENTS | ALZA CORPORATION (US) | 2005-11-03 | — | — | WO | claimed |
| US-20050226922-A1 | Apparatus and method for transdermal delivery of fentanyl-based agents | ALZA CORPORATION | 2005-10-13 | — | — | US | claimed |
| WO-2005042702-A2 | COMPOSITIONS OF STABILIZED DNA FOR COATING MICROPROJECTIONS | ALZA CORPORATION (US) | 2005-05-12 | — | — | WO | claimed |
| US-20050090009-A1 | Compositions of stabilized DNA for coating microprojctions | ALZA CORPORATION | 2005-04-28 | — | — | US | claimed |
| US-20050049549-A1 | Method and device for enhancing transdermal agent flux | ALZA CORPORATION | 2005-03-03 | — | — | US | claimed |
| WO-2005016441-A1 | METHOD AND DEVICE FOR ENHANCING TRANSDERMAL AGENT FLUX | ALZA CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| WO-2005016440-A1 | METHOD AND DEVICE FOR ENHANCING TRANSDERMAL AGENT FLUX | ALZA CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| US-20050031676-A1 | Method and device for enhancing transdermal agent flux | ALZA CORPORATION | 2005-02-10 | — | — | US | claimed |
| EP-0653438-A2 | Oligonucleotide compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200179346-A1 | PHARMACEUTICAL COMPOSITION | PEF1, FIBP, F2 | PTPN1 2337/4885CA2 1496/4885PTPN2 2377/4885 |
| US-20200155514-A1 | PHARMACEUTICAL COMPOSITION | FIBP, FGF2, F2 | PTPN1 2439/4885CA2 1141/4885PTPN2 2416/4885 |
| US-11759456-B2 | Pharmaceutical composition | PEF1, FIBP, F2 | PTPN1 2337/4885CA2 1496/4885PTPN2 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.